Ferric carboxymaltose in patients with heart failure and iron deficiency. by Anker, Stefan D et al.
Anker, SD; Comin Colet, J; Filippatos, G; Willenheimer, R; Dick-
stein, K; Drexler, H; L?scher, TF; Bart, B; Banasiak, W; Niegowska,
J; Kirwan, BA; Mori, C; von Eisenhart Rothe, B; Pocock, SJ; Poole-
Wilson, PA; Ponikowski, P; the FAIR-HF Trial Investigators (2009)
Ferric Carboxymaltose in Patients with Heart Failure and Iron Defi-
ciency. The New England journal of medicine, 361 (25). pp. 2436-48.
ISSN 0028-4793
Downloaded from: http://researchonline.lshtm.ac.uk/4510/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
original article
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;25 nejm.org december 17, 20092436
Ferric Carboxymaltose in Patients with Heart 
Failure and Iron Deficiency
Stefan D. Anker, M.D., Ph.D., Josep Comin Colet, M.D.,  
Gerasimos Filippatos, M.D., Ronnie Willenheimer, M.D.,  
Kenneth Dickstein, M.D., Ph.D., Helmut Drexler, M.D.,*  
Thomas F. Lüscher, M.D., Boris Bart, M.D., Waldemar Banasiak, M.D., Ph.D., 
Joanna Niegowska, M.D., Bridget-Anne Kirwan, Ph.D., Claudio Mori, M.D., 
Barbara von Eisenhart Rothe, M.D., Stuart J. Pocock, Ph.D.,  
Philip A. Poole-Wilson, M.D.,* and Piotr Ponikowski, M.D., Ph.D.,  
for the FAIR-HF Trial Investigators†
From the Department of Cardiology, 
Campus Virchow-Klinikum, Charité Uni-
versitätsmedizin, Berlin, and the Center 
for Clinical and Basic Research, San Raf-
faele, Rome (S.D.A.); Hospital del Mar 
and Universitat Autonoma de Barcelona, 
Barcelona (J.C.C.); Athens University Hos-
pital Attikon, Athens (G.F.); Heart Health 
Group and Lund University, Malmö, Swe-
den (R.W.); Stavanger University Hospital, 
Stavanger, and the University of Bergen, 
Bergen — both in Norway (K.D.); Medi-
zinische Hochschule Hannover, Hannover, 
Germany (H.D.); University Hospital Zü-
rich, Zurich (T.F.L.), SOCAR Research, Nyon 
(B.-A.K.), and Vifor Pharma, Glattbrugg 
(C.M., B.E.R.) — all in Switzerland; Rus-
sian State Medical University, Outpatient 
Diagnostic Consulting Center 1, Moscow 
(B.B.); Military Hospital, Wroclaw (W.B., 
P.P.); Centrum Medyczne, Telmont Cen-
trum Medyczne, Sp. z O.O., Warsaw (J.N.), 
and Medical University, Wroclaw (P.P.) — 
all in Poland; and London School of Hy-
giene and Tropical Medicine (S.J.P.) and 
the National Heart and Lung Institute, Im-
perial College London (P.A.P.-W.) — both 
in London. Address reprint requests to Dr. 
Anker at Applied Cachexia Research, De-
partment of Cardiology, Char ité Universi-
tätsmedizin Berlin, Campus Virchow-Klini-
kum. Augustenburger Pl. 1, D-13353 Berlin, 
Germany, or at s.anker@cachexia.de.
*Deceased.
†Members of the Ferinject Assessment 
in Patients with Iron Deficiency and 
Chronic Heart Failure (FAIR-HF) study 
group are listed in the Appendix.
This article (10.1056/NEJMoa0908355) was 
published on November 17, 2009, at NEJM.
org.
N Engl J Med 2009;361:2436-48.
Copyright © 2009 Massachusetts Medical Society.
A BS TR AC T
BACKGROUND
Iron deficiency may impair aerobic performance. This study aimed to determine 
whether treatment with intravenous iron (ferric carboxymaltose) would improve 
symptoms in patients who had heart failure, reduced left ventricular ejection frac-
tion, and iron deficiency, either with or without anemia.
METHODS
We enrolled 459 patients with chronic heart failure of New York Heart Association 
(NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for 
patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin 
level <100 μg per liter or between 100 and 299 μg per liter, if the transferrin saturation 
was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly as-
signed, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or 
saline (placebo). The primary end points were the self-reported Patient Global Assess-
ment and NYHA functional class, both at week 24. Secondary end points included the 
distance walked in 6 minutes and the health-related quality of life.
RESULTS
Among the patients receiving ferric carboxymaltose, 50% reported being much or 
moderately improved, as compared with 28% of patients receiving placebo, according 
to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence 
interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 
47% had an NYHA functional class I or II at week 24, as compared with 30% of pa-
tients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 
1.55 to 3.71). Results were similar in patients with anemia and those without anemia. 
Significant improvements were seen with ferric carboxymaltose in the distance on 
the 6-minute walk test and quality-of-life assessments. The rates of death, adverse 
events, and serious adverse events were similar in the two study groups.
CONCLUSIONS
Treatment with intravenous ferric carboxymaltose in patients with chronic heart 
failure and iron deficiency, with or without anemia, improves symptoms, functional 
capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov 
number, NCT00520780.)
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Recent developments in the manage-ment of chronic heart failure in patients with an impaired left ventricular ejection 
fraction have changed the natural history of this 
clinical syndrome and improved patients’ out-
comes.1,2 However, the normal daily activities 
of many patients with heart failure remain re-
stricted; they report symptoms of fatigue and 
dyspnea that adversely affect their quality of life, 
leading to high morbidity.3,4 Therapeutic options 
to improve functional capacity in patients with 
heart failure are limited, and novel therapies are 
needed.
Numerous mechanisms unrelated to hemody-
namic dysfunction may underlie impaired exercise 
tolerance in patients with chronic heart failure. 
Among them, inadequate oxygen supply and im-
paired oxygen use by skeletal muscle during exer-
cise contribute to poor clinical status.5,6 In addi-
tion, anemia may aggravate symptoms in patients 
with heart failure.7 Targeting these abnormalities 
may confer functional benefits to such patients.
Iron plays a key role in oxygen uptake, trans-
port, and storage, as well as oxidative metabolism 
in the skeletal muscle; it also is involved in eryth-
ropoiesis.8,9 Traditionally, iron deficiency has been 
considered to have clinical consequences only in 
the presence of anemia. Alternatively, a reduced 
hemoglobin level can be viewed as the end result 
of a process beginning with the gradual depletion 
of iron stores.9,10 Iron deficiency in patients with 
or without anemia attenuates aerobic performance 
and is accompanied by reports of fatigue and ex-
ercise intolerance.11 The repletion of iron in pa-
tients who have iron deficiency without heart 
failure improves cognitive, symptomatic, and ex-
ercise performance.12,13
Recently, it has been recognized that patients 
with heart failure may be prone to the develop-
ment of iron deficiency as a consequence of a 
depletion of iron stores or defective iron absorp-
tion and the reduced availability of iron recycled 
in the reticuloendothelial system.14,15 Four small 
studies showed that the correction of iron defi-
ciency with the use of intravenous iron in pa-
tients with chronic heart failure may result in 
clinical benefits.16-19 In one of these studies,17 
the symptomatic benefit was similar in patients 
with anemia and those without anemia. We de-
signed our randomized, double-blind study, called 
the Ferinject Assessment in Patients with Iron 
Deficiency and Chronic Heart Failure (FAIR-HF) 
trial, to determine whether the correction of iron 
deficiency with the use of intravenous iron (ferric 
carboxymaltose) confers symptomatic benefits in 
patients with chronic heart failure.
Me thods
Trial Design and Oversight
From June 25, 2007, through December 31, 2008, 
a total of 459 eligible patients were enrolled from 
75 sites in 11 countries (Fig. 1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). The study design has been 
published previously.20 The protocol was approved 
by the institutional review board at each partici-
pating center, and the trial was conducted in ac-
cordance with the principles of the Declaration 
of Helsinki, the International Conference on Har-
monization Good Clinical Practice guidelines, and 
local and national regulations. Written informed 
consent was provided by all patients before any 
study-related procedures were performed.
The trial was designed, implemented, and over-
seen by the FAIR-HF Executive Committee, to-
gether with representatives of the sponsor, Vifor 
Pharma (Glattbrugg, Switzerland). ClinStar (Mos-
cow) was responsible for on-site monitoring of 
sites in Russia and Ukraine. Kendle (Munich, Ger-
many) was responsible for on-site monitoring in 
other countries, in addition to data collection and 
data management. SOCAR Research (Nyon, Swit-
zerland) was responsible for data analysis. Anal-
yses were performed independently of the spon-
sor, according to a predefined plan of statistical 
analysis. The medical statistics unit at the Lon-
don School of Hygiene and Tropical Medicine 
performed the same analyses, separately, with 
identical results. The manuscript was prepared and 
submitted for publication by the FAIR-HF Execu-
tive Committee. An independent data and safety 
monitoring board reviewed the safety data on an 
ongoing basis. The authors had access to the study 
data and vouch for the accuracy and completeness 
of the reported data and analyses.
Recruitment and Follow-up of Study Patients
Eligible subjects included ambulatory patients who 
had chronic heart failure of New York Heart As-
sociation (NYHA) class II or III, a left ventricular 
ejection fraction of 40% or less (for patients in 
NYHA class II) or 45% or less (for patients in 
NYHA class III), a hemoglobin level at the screen-
ing visit between 95 and 135 g per liter, and iron 
deficiency. The presence or absence of iron defi-
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ciency was determined on the basis of results re-
ceived from the central laboratory. Iron deficien-
cy was diagnosed when the serum ferritin level 
was less than 100 μg per liter or was between 100 
and 299 μg per liter when the transferrin satura-
tion was less than 20%. Patients were excluded if 
they had uncontrolled hypertension, other clini-
cally significant heart disease, inflammation, or 
clinically significantly impaired liver or renal 
function.
Table 1. Baseline Demographic and Clinical Characteristics of the Study Patients in the Intention-to-Treat Population, 
According to Study Group.*
Variable
Ferric Carboxymaltose  
(N = 304)
Placebo  
(N = 155)
Age — yr 67.8±10.3 67.4±11.1
Female sex — no. (%) 159 (52.3) 85 (54.8)
White race — no. (%)† 303 (99.7) 155 (100.0)
NYHA class — no. (%)
II 53 (17.4) 29 (18.7)
III 251 (82.6) 126 (81.3)
Left ventricular ejection fraction — % 31.9±5.5 33.0±6.1
Body weight — kg 77.0±14.2 77.6±16.3
Body-mass index‡ 28.0±4.8 28.1±5.1
Blood pressure — mm Hg
Systolic 126±15 126±15
Diastolic 77±9 76±10
Pulse — beats/min 71±11 72±12
6-Minute walk test distance — m 274±105 269±109
Ischemic cause of heart failure — no. (%) 245 (80.6) 123 (79.4)
Cardiovascular risk factor — no. (%)
Hypertension, treated with drugs 243 (79.9) 128 (82.6)
Dyslipidemia, treated with drugs 144 (47.4) 70 (45.2)
Diabetes mellitus 93 (30.6) 37 (23.9)
Atrial fibrillation 94 (30.9) 44 (28.4)
Medical history — no. (%)
Myocardial infarction 168 (55.3) 90 (58.1)
Angina pectoris 171 (56.3) 89 (57.4)
Stroke 24 (7.9) 9 (5.8)
Coronary revascularization 64 (21.1) 31 (20.0)
Laboratory measurements
Hemoglobin — g/liter 119±13 119±14
Mean corpuscular volume — μm3 91.6±8.1 91.7±6.7
Serum ferritin — μg/liter 52.5±54.5 60.1±66.5
Transferrin saturation — %§ 17.7±12.6 16.7±8.4
C-reactive protein — mg/liter 7.46±5.34 9.12±5.48
Sodium — mmol/liter 141±3 141±3
Potassium — mmol/liter 4.65±0.61 4.58±0.52
Alanine aminotransferase — U/liter 20.5±12.3 18.8±8.1
Aspartate aminotransferase — U/liter 23.1±10.4 22.4±7.2
Creatinine — mg/dl 1.2±0.6 1.2±0.6
Estimated glomerular filtration rate —  
ml/min/1.73 m2 of body-surface area¶
63.8±21.2 64.8±25.3
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Table 1. (Continued.)
Ferric Carboxymaltose  
(N = 304)
Placebo  
(N = 155)
Concomitant treatment — no. (%)
Diuretic 280 (92.1) 140 (90.3)
ACE inhibitor or ARB 281 (92.4) 141 (91.0)
Digitalis glycoside 46 (15.1) 25 (16.1)
Beta-blocker 262 (86.2) 129 (83.2)
Antiplatelet therapy 189 (62.2) 97 (62.6)
Anticoagulant therapy 67 (22.0) 22 (14.2)
Lipid-lowering therapy 142 (46.7) 72 (46.5)
Insulin 27 (8.9) 9 (5.8)
Oral hypoglycemic agent 49 (16.1) 22 (14.2)
* Plus–minus values are means ±SD. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ACE 
denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and NYHA New York Heart Association.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The percent transferrin saturation was calculated as iron (in micromoles per liter) ÷ transferrin (in grams per li-
ter) × 25.1.
¶ The estimated glomerular filtration rate was calculated by the central laboratory according to the Modification of Diet in 
Renal Disease formula: 186 × (serum creatinine [in micromoles per liter] ÷ 88.4) − 1.154 × age (in years) − 0.203 × 1.21 (if pa-
tient is black) × 0.742 (if patient is female).
Randomization
Before the iron-correction phase was begun, a clin-
ical history, physical examination, 6-minute walk 
test results, and 12-lead electrocardiogram were 
obtained for each patient. We also performed as-
sessments of the health-related quality of life in all 
patients. Using a central interactive voice-response 
system, we randomly assigned eligible patients, 
in a 2:1 ratio, to receive either ferric carboxymalt-
ose (provided by Vifor Pharma) or placebo (normal 
saline).
Study Therapy and Blinding
The total iron dose required for iron repletion was 
calculated at baseline, according to Ganzoni’s for-
mula21 and the mean of the two hemoglobin val-
ues obtained during the screening period. The fer-
ric carboxymaltose or saline was administered as 
an intravenous bolus injection of 4 ml (which is 
the amount of ferric carboxymaltose in a water 
solution for injection that is equivalent to 200 mg 
of iron). The dosing frequency was weekly until 
iron repletion was achieved (the correction phase) 
and then every 4 weeks during the maintenance 
phase, which started at week 8 or week 12, de-
pending on the required iron-repletion dose.
Because ferric carboxymaltose is a dark-brown 
solution that is easily distinguishable from the 
saline placebo, study personnel responsible for the 
preparation and administration of the study drug 
(including at least one physician) were aware of 
the group assignments and therefore were not in-
volved in any study assessments. To ensure that 
patients were unaware of the study drug they were 
receiving, black syringes were used to adminis-
ter the study treatment and a curtain (or some-
thing similar) was used to shield the injection site 
from the patient’s view.
The central laboratory sent results regarding 
measures of iron metabolism and hemoglobin 
only to the study personnel who were aware of 
the group assignments. These persons were re-
sponsible for evaluating for the presence of ele-
vated iron-metabolism measurements or severe 
anemia and for implementing the following pro-
cedures, as defined in the protocol. If the ferritin 
level exceeded 800 μg per liter or was between 
500 and 800 μg per liter with a transferrin satura-
tion of more than 50%, or if the hemoglobin level 
was higher than 160 g per liter, ferric carboxymalt-
ose was discontinued and placebo was given in-
stead. In this case, the ferritin, transferrin satu-
ration, and hemoglobin levels were reassessed. 
After the ferritin level had dropped to less than 
400 μg per liter, the transferrin saturation to un-
der 45%, and the hemoglobin level to less than 
160 g per liter, treatment with ferric carboxymalt-
ose could be restarted. If severe anemia (hemo-
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globin level, ≤90 g per liter) developed, the study 
treatment was permanently discontinued. The fol-
low-up of such patients continued, and further 
management of anemia was performed at the in-
vestigator’s discretion.
In addition to the dosing visits, at weeks 4, 12, 
24, and 26, patients were assessed for efficacy and 
safety.
Primary and Secondary End Points
The primary end points were the self-reported Pa-
tient Global Assessment (Fig. 2 in the Supplemen-
tary Appendix) and NYHA functional class (adjust-
ed for the class at baseline) at week 24. Secondary 
end points included the self-reported Patient Global 
Assessment and NYHA functional class at week 
4 and week 12, as well as the distance on the 6-min-
ute walk test and the overall score on the Kansas 
City Cardiomyopathy questionnaire22 (on which 
the overall score ranges from 0 to 100, with a high-
er score indicating a better quality of life) and the 
European Quality of Life–5 Dimensions (EQ-5D) 
Visual Analog Scale23 (on which the score ranges 
from 0 to 100, with a higher score indicating bet-
ter health) at weeks 4, 12, and 24 (all adjusted for 
the baseline data).
Safety end points were serious and nonseri-
ous adverse events, hospitalization, and death, 
as assessed up to week 26. Standardized defini-
tions for the causes of death and hospitalization 
were developed by members of the FAIR-HF Ex-
ecutive Committee and were supplied to all in-
vestigators.20
Statistical Analysis
Data analysis for efficacy was performed accord-
ing to the intention-to-treat principle for each as-
signed study group. The planned sample size of 
402 patients — 268 in the ferric carboxymaltose 
group and 134 in the placebo group — was cal-
culated on the basis of assumptions that the study 
would have a statistical power of 90% (with a two-
sided alpha of 0.025) to detect a mean difference 
in the NYHA class of 0.50 and in the self-reported 
Patient Global Assessment ranking of 0.90 (the 
primary end points) between the two study groups. 
Assuming that 10% of patients would not com-
plete the week 24 visit, the planned sample size 
was increased to 442. Both primary end points 
were compared between the two study groups by 
means of polytomous regression.24 For data on the 
NYHA class, the model was adjusted for the base-
line value. The alpha value was adjusted accord-
ing to the method of Benjamini and Hochberg.25
Missing data on the NYHA class and the self-
reported Patient Global Assessment were imputed 
from data collected during the previous follow-up 
visit, according to the last–observation-carried-
forward method, for patients who were known 
to be alive and not hospitalized at the time of the 
assessment. For hospitalized patients, a missing 
NYHA class was assigned as class IV and a miss-
ing self-reported Patient Global Assessment was 
assigned as “much worse.” For patients who had 
died, a missing NYHA class was assigned as 
Figure 1 (facing page). Self-Reported Patient Global  
Assessment and New York Heart Association (NYHA) 
Functional Class at Week 24, According to Assigned 
Study Treatment.
Panel A shows the data regarding the self-reported Pa-
tient Global Assessment, and Panel B, data regarding 
the NYHA functional class. The odds ratio for an im-
provement in the self-reported Patient Global Assess-
ment with ferric carboxymaltose as compared with pla-
cebo was 2.51 (95% confidence interval [CI], 1.75 to 3.61; 
P<0.001). Data on the self-reported Patient Global Assess-
ment were missing for 30 patients known to be alive and 
not in the hospital at week 24 (18 receiving ferric carboxy-
maltose and 12 receiving placebo); for these patients, 
the last available assessment was used as the assess-
ment for week 24. The two patients who were hospital-
ized at 24 weeks (both receiving ferric carboxymaltose) 
were assigned an assessment of much worse. The 9 pa-
tients who died before week 24 (5 who had been receiv-
ing ferric carboxymaltose and 4 who had been receiving 
placebo) were categorized as dead. Panel A does not in-
clude 12 patients in the ferric carboxymaltose group and 
6 in the placebo group who were known to be alive at 
week 24 but who had no data on the self-reported Pa-
tient Global Assessment at any time during the study. 
The odds ratio for an improved NYHA class with ferric 
carboxymaltose as compared with placebo was 2.40 
(95% CI, 1.55 to 3.71; P<0.001). Data on the NYHA class 
were missing for 28 patients known to be alive and not 
in the hospital at week 24 (16 receiving ferric carboxy-
maltose and 12 receiving placebo); for these patients, 
the last available NYHA classification was used as the 
classification for week 24. The 2 patients who were hos-
pitalized at 24 weeks (both receiving ferric carboxymal-
tose) were considered to have NYHA class IV. The 9 pa-
tients who died before week 24 (5 who had been receiving 
ferric carboxymaltose and 4 who had been receiving pla-
cebo) were categorized as being dead (having NYHA 
class V). The data in Panel B do not include data for 10 
patients in the ferric carboxymaltose group and 5 in the 
placebo group who were known to be alive at week 24 
but who had no data on the NYHA functional class at 
any time during the study. In both panels, percentages 
may not sum to 100 because of rounding.
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class V and a missing self-reported Patient Global 
Assessment was assigned as “died.” The analysis 
regarding the primary end points was restricted 
to data for patients who had at least one valid 
self-reported Patient Global Assessment or NYHA 
value, respectively, during the follow-up period.
For the continuous variables, changes from the 
baseline value and values at weeks 4, 12, and 24 
were compared between the ferric carboxymaltose 
group and the placebo group by comparing the 
means within each of the two study groups at 
each visit with the use of a model for repeated 
measures adjusted for baseline values. For cate-
gorical end points, differences in the distribution 
for each of the two study groups were tested by 
means of ordered polytomous regression. Tests 
for interaction were performed as part of the sub-
group analysis regarding the primary end points 
by adding an interaction term to the ordered poly-
tomous regression model. Cox proportional-haz-
ards regression models were used to estimate the 
hazard ratios for safety outcomes on the basis of 
the treatment received. Event rates are reported 
per person-year at risk. All analyses were con-
ducted with the use of SAS software, version 9.1 
(SAS Institute).
R esult s
Characteristics of the Study Patients
The clinical characteristics of 459 patients are pre-
sented in Table 1. A total of 304 patients were ran-
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domly assigned to receive ferric carboxymaltose 
and 155 to receive placebo. The two groups were 
similar with respect to the baseline clinical and 
laboratory characteristics and the use of cardio-
vascular medications at the time of enrollment.
Follow-up
Of the 304 patients assigned to receive ferric car-
boxymaltose, 26 (8.6%) did not complete the 24 
weeks of follow-up; of these 26, 5 had died and 21 
had withdrawn (Fig. 1 in the Supplementary Ap-
pendix). Of the 155 patients assigned to receive 
placebo, 20 (12.9%) did not complete the 24 weeks 
of follow-up; of these 20, 4 had died and 16 had 
withdrawn.
Primary End Points
The self-reported Patient Global Assessment at 
week 24 was improved in the ferric carboxymaltose 
group, with 50% of patients reporting that they 
were much or moderately improved, as compared 
with 28% of patients in the placebo group (odds 
ratio for being in a better rank, 2.51; 95% confi-
dence interval [CI], 1.75 to 3.61; P<0.001) (Fig. 1A). 
Similarly, the NYHA functional class at week 24, 
after adjustment for the baseline value was im-
proved in the ferric carboxymaltose group, with 
47% having an NYHA functional class I or II, as 
compared with 30% in the placebo group (odds 
ratio for improvement by one class, 2.40; 95% CI, 
1.55 to 3.71; P<0.001) (Fig. 1B). 
Secondary End Points
The use of ferric carboxymaltose, as compared with 
placebo, significantly improved the self-reported 
Patient Global Assessment and NYHA class at 
weeks 4 and 12 (P<0.001 for all comparisons) (Fig. 
2A and 2B, and Fig. 3 and 4 in the Supplemen-
tary Appendix). Significant improvements were 
also seen in the distance on the 6-minute walk 
test and in the quality of life, as evaluated by the 
EQ-5D visual assessment score and the overall 
Kansas City Cardiomyopathy score, at weeks 4, 
12, and 24 (P<0.001 for all comparisons) (Fig. 2C, 
2D, and 2E).
Subgroup Analyses
A consistent benefit regarding the two primary end 
points was observed in all prespecified subgroups 
(Fig. 3). The treatment effect was similar in pa-
tients with anemia and in those without anemia 
(prospectively defined as a hemoglobin level ≤120 g 
per liter at baseline).
Safety and Biochemical Analyses
Survival status was available for all patients through 
at least week 24. The rates of death, hospitalization, 
and serious and nonserious adverse events reported 
by the investigators were similar in the two study 
groups (Table 2). There was a trend toward a lower 
rate of first hospitalization for any cardiovascular 
reason among patients receiving ferric carboxy-
maltose as compared with those receiving placebo 
(hazard ratio, 0.53; 95% CI, 0.25 to 1.09; P = 0.08). 
The hazard ratio for death or first hospitalization 
for any cardiovascular reason among patients who 
received ferric carboxymaltose as compared with 
those who received placebo was 0.61 (95% CI, 0.32 
to 1.18; P = 0.14).
Data on serious and nonserious adverse events 
are also shown in Table 2, and in Table 1 in the 
Supplementary Appendix. The study treatment 
Figure 2 (facing page). Main Secondary Outcomes  
during the Study, According to Assigned Study  
Treatment.
Shown are data across the study period for the self- 
reported Patient Global Assessment (Panel A), the 
New York Heart Association (NYHA) functional class 
(Panel B), change in distance on the 6-minute walk test 
(Panel C), the change in the score on the European 
Quality of Life–5 Dimensions (EQ-5D) Visual Analog 
Scale (on which the score ranges from 0 to 100, with 
higher scores indicating better health) (Panel D), and 
the change in the overall score on the Kansas City Car-
diomyopathy questionnaire (on which the overall score 
ranges from 0 to 100, with a higher score indicating a 
better quality of life) (Panel E). The data in Panels A 
and B are odds ratios, for the ferric carboxymaltose 
(FCM) group as compared with the placebo group and 
shown on a log2 scale, of being in a better assessment 
category (Panel A) or NYHA functional class (Panel B). 
In both panels, for data on the self-reported Patient 
Global Assessment that were missing for patients 
known to be alive and not in the hospital at each time 
point, the last available assessment was used. Patients 
who were hospitalized at each time point were given 
an assessment of much worse (in Panel A) or an 
NYHA class of IV (in Panel B). Patients who died be-
fore week 24 were categorized as dead (in Panel B, cor-
responding to NYHA class V). Data were not included 
for patients who were known to be alive at the time 
point but had no previous data. For Panel A, the odds 
ratios at week 4 and week 12 are 3.44 (95% confidence 
interval [CI], 2.34 to 5.07) and 3.19 (95% CI, 2.20 to 
4.63). In Panel B, the odds ratios at week 4 and week 
12 are 3.96 (95% CI, 1.98 to 7.93) and 3.42 (95% CI, 
2.04 to 5.72). Panels C, D, and E show the mean (±SE) 
changes in the variable at weeks 4, 12, and 24. In those 
panels, the P values are for the comparison between 
the two study groups, and the I bars denote the stan-
dard error.
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was stopped prematurely in 16 (5.3%) of the 304 
patients assigned to receive ferric carboxymaltose 
and in 14 (9.0%) of the 155 patients assigned to 
receive placebo. No severe allergic reactions re-
lated to the study treatment were reported. Of 
the patients treated with ferric carboxymaltose, 
injection-site discoloration was reported for four 
patients and injection-site pain for two patients.
Laboratory values for ferritin, transferrin sat-
uration, and hemoglobin at week 24 were signifi-
cantly different between the two study groups 
(P<0.001 for all comparisons) (Table 3). The mean 
(±SE) difference in the ferritin level (adjusted for 
baseline) between patients receiving ferric car-
boxymaltose and those receiving placebo was 
243±17 μg per liter at week 4, 188±15 μg per liter 
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Figure 3. Self-Reported Patient Global Assessment and New York Heart Association (NYHA) Functional Class in Predefined Subgroups, 
According to Assigned Study Treatment.
The number of patients in each subgroup for whom data were available is shown. The odds ratios are given for the ferric carboxymaltose 
group, as compared with the placebo group, on a log2 scale. For the results regarding the NYHA functional class in the subgroup of pa-
tients with heart failure of NYHA class II, one patient receiving ferric carboxymaltose had improvement to NYHA class I and two pa-
tients receiving placebo had a worsening to NYHA class III. The body-mass index (BMI) is the weight in kilograms divided by the square 
of the height in meters. CI denotes confidence interval, GFR glomerular filtration rate, and LV left ventricular.
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at week 12, and 246±20 μg per liter at week 24 
(P<0.001 for all comparisons). The corresponding 
mean differences in the hemoglobin level were 
6.6±1.1, 10.6±1.3, and 5.9±1.5 g per liter, respec-
tively (P<0.001 for all comparisons), and the cor-
responding mean differences in the mean corpus-
cular volume of erythrocytes were 1.5±0.4, 2.4±0.5, 
and 2.7±0.7 μm3, respectively (all P<0.001). The 
mean difference in the hemoglobin level at week 
24 (adjusted for baseline) between the ferric car-
boxymaltose group and the placebo group was not 
significant among patients who did not have ane-
mia at baseline (2.4±2.0 g per liter, P = 0.21) but 
was significant among patients who had anemia 
at baseline (9.1±2.2 g per liter, P<0.001). The mean 
difference in estimated glomerular filtration rate 
(adjusted for baseline) between patients receiving 
ferric carboxymaltose and those receiving placebo 
was 3.8±1.8 ml per minute (P = 0.03). There were 
no significant differences between the two study 
groups with respect to adverse-event reporting 
based on chemical values and other hematologic 
laboratory test results.
Discussion
Treatment with ferric carboxymaltose for 24 weeks 
in patients who had chronic heart failure and iron 
deficiency with or without anemia improved symp-
toms, functional capacity, and the quality of life. 
Table 2. Safety End Points and Serious and Nonserious Adverse Events, According to Study Treatment Received.*
End Point or Event
Ferric Carboxymaltose  
(N = 305)
Placebo  
(N = 154) P Value
No. of End 
Points or 
Serious 
Adverse/ 
Any Adverse 
Events
No. of Patients  
with End Point  
or Event  
(incidence/ 
100 patient-yr  
at risk)
No. of End 
Points or 
Serious 
Adverse/ 
Any Adverse 
Events
No. of Patients  
with End Point  
or Event  
(incidence/ 
100 patient-yr  
at risk)
Safety end point
Death 5 5 (3.4) 4 4 (5.5) 0.47
Death due to cardiovascular causes 4 4 (2.7) 4 4 (5.5) 0.31
Death due to worsening heart failure 0 0 3 3 (4.1)
First hospitalization 28 25 (17.7) 22 17 (24.8) 0.30
Hospitalization for any cardiovascular cause 16 15 (10.4) 18 14 (20.0) 0.08
Hospitalization for worsening heart failure 7 6 (4.1) 9 7 (9.7) 0.11
Any hospitalization or death 33 30 (21.2) 26 19 (27.7) 0.38
Hospitalization for any cardiovascular cause or death 21 20 (13.9) 22 16 (22.9) 0.14
First hospitalization for worsening heart failure or death 12 11 (7.5) 13 10 (13.9) 0.15
Investigator-reported adverse event
Cardiac disorder 12/46 38 (27.6) 23/49 33 (50.2) 0.01
Gastrointestinal disorder 2/29 24 (16.9) 2/7 5 (6.9) 0.06
General disorder or injection-site condition 4/28 23 (16.2) 1/6 6 (8.3) 0.14
Injection-site pain or discoloration 0/6 6 (4.1) 0/0 0
Infection or infestation 2/56 50 (37.0) 0/32 24 (35.8) 0.97
Abnormal laboratory test, vital sign, or physical finding 0/63 32 (23.0) 0/10 10 (14.0) 0.17
Nervous system disorder 3/29 22 (15.6) 3/20 14 (20.3) 0.44
Respiratory, thoracic, or mediastinal disorder 0/9 9 (6.2) 3/13 10 (14.2) 0.06
Vascular disorder 3/24 20 (14.0) 1/13 11 (15.7) 0.80
* Adverse events are classified on the basis of the system organ classes of the Medical Dictionary for Regulatory Activities. Events that were re-
ported in more than 4% of all the study patients are listed here. One patient who had been randomly assigned to the placebo group re-
ceived ferric carboxymaltose.
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Our study also showed that treatment with ferric 
carboxymaltose was not associated with an un-
acceptable side-effect or adverse-event profile.
Our study showed improvement with ferric 
carboxymaltose in the two primary end points: 
the self-reported Patient Global Assessment and 
the NYHA class at 24 weeks. The benefit was evi-
dent after 4 weeks and was maintained through-
out the study period. These results were consistent 
across all prespecified subgroups and were con-
firmed by the observed improvements in distance 
on the 6-minute walk test distance and in scores 
on the health-related quality-of-life questionnaires.
Our patient population was identified on the 
basis of laboratory biomarkers, ferritin, transfer-
rin saturation, and hemoglobin. These variables 
were also used to calculate the iron-repletion dose 
and to guide decisions about continuation or in-
terruption of ferric carboxymaltose. In that sense, 
the trial is a double-blind treatment trial that used 
guidance based on blood-sample data for study-
treatment initiation and monitoring. The study 
results suggest that in the assessment of ambu-
latory patients with symptomatic heart failure and 
systolic dysfunction, laboratory investigations to 
detect iron deficiency may be useful in routine 
practice to decide whether symptom management, 
by means of treatment with intravenous iron, is 
indicated.
The dose needed to correct iron deficiency was 
calculated according to Ganzoni’s formula21 and 
was provided over a period between 3 and 7 weeks 
(a median of six injections) during the correction 
phase. We required that iron was given in doses 
of 200 mg per application and that the dosing 
frequency was weekly during the correction phase 
and monthly during the maintenance phase. The 
results of our study are applicable only to this 
dosing regimen. Treatment approaches involv-
ing higher doses and higher ferritin thresholds 
for the interruption of therapy are untested in 
patients with heart failure.
The treatment with ferric carboxymaltose was 
beneficial to both patients with anemia and those 
without anemia. This suggests that iron deficiency 
is a valid independent therapeutic target. Iron me-
tabolism in patients with chronic illness merits a 
more detailed investigation to unravel the reasons 
why the correction of iron deficiency can result 
in symptomatic improvements even in the absence 
of a change in hemoglobin. Our results are con-
sistent with those from four small studies that 
Table 3. Levels of Iron-Metabolism Markers and Hemoglobin at Week 24 According to Study Treatment.*
Variable
Ferric Carboxymaltose 
(N = 305)
Placebo 
(N = 154) P Value
All patients
Ferritin (μg/liter) 312±13 74±8 <0.001
Transferrin saturation (%)† 29±1 19±1 <0.001
Hemoglobin (g/liter) 130±1 125±1 <0.001
Mean corpuscular volume (μm3) 97±0 94±1 <0.001
Patients with anemia (hemoglobin ≤120 g/liter)
Ferritin (μg/liter) 275±18 68±11 <0.001
Transferrin saturation (%)† 29±1 17±1 <0.001
Hemoglobin (g/liter) 127±1 118±2 <0.001
Mean corpuscular volume (μm3) 98±1 93±1 <0.001
Patients without anemia (hemoglobin >120 g/liter)
Ferritin (μg/liter) 349±19 80±11 <0.001
Transferrin saturation (%)† 30±1 22±1 <0.001
Hemoglobin (g/liter) 133±1 132±1 0.21
Mean corpuscular volume (μm3) 96±1 95±1 0.91
* Plus–minus values are means ±SE. The P value is for the mean treatment effect, adjusted for the baseline value. One 
patient who had been randomly assigned to the placebo group received ferric carboxymaltose.
† The percent transferrin saturation was calculated as iron (in micromoles per liter) ÷ transferrin (in grams per li-
ter) × 25.1.
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were performed with the use of a different prepa-
ration of intravenous iron.16-19 One of these stud-
ies15 recruited a subgroup of patients without 
anemia who had even higher hemoglobin levels 
than our patients (i.e., 125 to 145 g per liter). We 
do not know the limit of hemoglobin up to which 
iron deficiency is pathophysiologically important. 
On the basis of our current findings, we cannot 
recommend treatment with ferric carboxymaltose 
for patients who have chronic heart failure, iron 
deficiency, and a hemoglobin level above 135 g per 
liter, but such therapy is an area of interest for 
future research.
In conclusion, in stable, symptomatic, ambula-
tory patients with chronic heart failure, an im-
paired left ventricular ejection fraction, and iron 
deficiency, treatment with ferric carboxymaltose 
over a 24-week period improves symptoms, phys-
ical performance, and the quality of life and has 
acceptable side-effect and adverse-event profiles. 
The benefit was seen in patients with anemia and 
in those without anemia.
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